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Purpose Tacrolimus pharmacokinetics and calcineurin activity in peripheral blood mononuclear cells 
(PBMC) was investigated in adult patients undergoing primary living-donor liver transplantation (LDLT) 
in order to clarify the significance of trough monitoring of blood tacrolimus concentration during the early 
post-transplantation period.  
Methods Fourteen patients were enrolled in this study, and time-course data after oral administration of a 
conventional tacrolimus formulation twice a day were obtained at 1 and 3 weeks after transplantation.  
The concentration of tacrolimus in whole blood and calcineurin activity in PBMC was measured.  
Results The apparent clearance of tacrolimus significantly increased at 3 weeks compared with 1 week 
after transplantation, although the trough concentration did not significantly differ at 1 and 3 weeks after 
transplantation.  The concentration at each sampling time, except at 1 h post-dose, was well correlated 
with the area under the concentration-time curve from 0 to 12 h (AUC0–12).  Neither the concentration at 
the trough time point nor AUC0–12 was correlated with the area under the calcineurin activity-time curve 
from 0 to 12 h; calcineurin activity at the trough time point, however, was strongly correlated (r2>0.92).   
Conclusions Trough concentration monitoring was appropriate for routine tacrolimus dosage adjustment in 
adult LDLT patients.  In addition, monitoring of calcineurin activity at the trough time point could be 








Tacrolimus, a calcineurin (CN) inhibitor, has been widely used to prevent acute rejections after liver 
transplantation, and therapeutic drug monitoring (TDM) of this drug is recommended to adjust dosages 
because of its narrow therapeutic index [1, 2].  Despite the large inter-individual variation in tacrolimus 
pharmacokinetics, the area under the concentration-time curve (AUC) versus the trough blood 
concentration (C0) has a nearly linear relationship [3, 4], and C0 of tacrolimus is usually monitored in 
patients receiving this drug.  However, in some cases of renal transplantation, the correlation between C0 
and the AUC of tacrolimus is not adequate [5].  With cyclosporine, another CN inhibitor, C0 does not 
correlate well with systemic drug exposure, and blood concentrations at 2 h post-dose (C2) have been 
shown to be good predictors for the absorption profile [6].  Levy et al. [7] reported that a new monitoring 
strategy based on C2 levels was superior to traditional C0 monitoring for liver transplant recipients in 
reduction of the incidence and severity of acute rejections.  Therefore, the relationship between C0 and 
AUC of tacrolimus should be clarified in adult LDLT patients, because the pharmacokinetics of tacrolimus 
during the early post-transplantation period may fluctuate widely, according to the regeneration of grafted 
liver [8, 9].    
The measurement of CN phosphatase activity in circulating blood is a pharmacodynamic approach 
for evaluating the immunosuppressive effect of CN inhibitors [10].  We found that tacrolimus and 
cyclosporine had different inhibitory effects on CN activity in peripheral blood mononuclear cells 
  
3 
(PBMCs) in de novo LDLT patients [11].  CN activity at trough time points represents a surrogate 
predictor for overall CN activity throughout the dosing intervals after cyclosporine administration in LDLT 
patients [12].  However, there is little information about the relationship between the overall CN activity 
throughout the dosing intervals and blood tacrolimus concentrations, and CN activity at trough time points, 
after oral administration of tacrolimus in this population.  
This study was designed to evaluate pharmacokinetic profiles in parallel with CN activity in PBMCs 
at 1 and 3 weeks after LDLT in adult patients.  Our aim was to evaluate the relationship between blood 
tacrolimus concentration at each sampling time and drug exposure during the dosing intervals, as well as 
CN activity during the dosing intervals, to clarify the significance of trough monitoring of tacrolimus blood 
concentration during the early post-transplantation phase.  
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Patients and methods 
Study design 
Patients more than 18 years old and who underwent primary LDLT between November 2007 and 
February 2009 at the Department of Transplantation and Immunology, Kyoto University Hospital were 
included in this study.  Patients who suffered from fulminant hepatitis or were co-administered 
medications incompatible with tacrolimus were excluded.  The study was discontinued when the 
administration of tacrolimus was stopped.  The study protocol conformed to the ethical guidelines of the 
Declaration of Helsinki as reflected in a priori approval by the Kyoto University Graduate School and the 
Faculty of Medicine Ethics Committee.  Written informed consent was obtained from each patient. 
Within 12 h after LDLT, we started immunosuppression with a conventional tacrolimus formulation 
(Prograf; Astellas Pharma Inc., Tokyo, Japan) and low-dose corticosteroids.  The initial oral dose of 
tacrolimus was 0.05 mg/kg twice daily (0900 hours and 2100 hours), and the dose was adjusted to target 
blood tacrolimus concentrations according to the trough measurements during the 3 weeks after 
transplantation.  The target C0 was set between 10 and 15 ng/ml on postoperative days (PODs) 1–7, 
between 8 and 12 ng/ml on PODs 8–14, and between 6 and 10 ng/ml after POD 15, using a microparticle 
enzyme immunoassay (MEIA) method with an IMx analyzer (Abbott Japan Co. Ltd., Tokyo, Japan).  
Corticosteroids were administered according to a protocol described previously [11].   
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Blood samples (2 ml) were taken before and at 1, 2, 4, 8, and 12 h after the morning administration 
on POD 6 or 8 (at 1 week) and POD 20 or 22 (at 3 weeks) in order to evaluate the effects of time after 
transplantation on pharmacokinetics and pharmacodynamics of tacrolimus.  The concentration of 
tacrolimus in whole blood was measured using three analytical methods: high-performance liquid 
chromatography with tandem mass spectrometry (LC/MS/MS), as previously reported [13]; the MEIA 
method; and the enzyme-multiplied immunoassay instrument (EMIT) method, using the Viva-E System 
(Siemens Healthcare Diagnostics, Tokyo, Japan).  Samples were assayed as soon as possible after blood 
collection and preserved at -20°C before the assay if necessary.   
CN phosphatase activity in PBMCs was measured using the remainder of the blood sample after 
blood concentration measurements, as an index of the pharmacological effects of tacrolimus.  The assay 
of CN phosphatase activity in PBMCs was performed by use of〔ϒ-phosphorus32〕regulatory subunit type 
II (RII) phosphopeptide as a substrate, according to a procedure described previously [11].  On the day of 
transplantation, we obtained a blood sample to determine the baseline CN activity (CNbase) before the 
administration of tacrolimus in each patient.  
 
Pharmacokinetic and pharmacodynamic analysis 
The AUC from 0 to 12 h (AUC0–12) after tacrolimus administration was calculated according to the 
trapezoidal rule.  The highest observed concentration and associated time point were defined as the 
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maximum drug concentration (Cmax) and the time at which the maximum concentration occurs (tmax), 
respectively.  The apparent clearance (CL/F) was calculated by dividing the morning dose on each study 
day with the AUC0–12.  The area under the CN activity-time curve from 0 to 12 h (AUA0–12) after 
administration was calculated according to the trapezoidal rule.  The greatest observed CN inhibition, 
which caused a nadir of enzyme activity, and its associated time points were defined as the maximum CN 
inhibition (CNnadir) and the corresponding time (tnadir), respectively.  The relationship between the blood 
tacrolimus concentration and CN activity in PBMCs was analyzed using the following maximum 
inhibitory effect (Emax) model:    
CN = Emax - Emax • C/(EC50 + C), 
where CN is the CN activity at blood concentration C; Emax is the maximum inhibitory effect attributable to 
the drug, which is assumed to be the same as the baseline activity; and EC50 is the blood concentration that 
gives a half-maximal effect.  The fixed parameters (θ) for Emax and EC50, were estimated by use of the 
nonlinear mixed effects modeling program NONMEM version 6.2 (ICON Development Solutions, Ellicott 
City, MD), and inter-individual variability (η) for Emax and EC50 and residual variability (ε) were assumed 





Data are presented as the mean ± standard deviation (SD).  Statistical analyses were performed 
using the statistical software package GraphPad Prism 5 (GraphPad Software, Inc., San Diego, CA).  The 
statistical significance of differences in mean values between 2 groups was analyzed using the paired t test.  
Pearson’s correlation coefficient (r) was used to estimate correlations between 2 factors.  A value of P < 




Measurement of blood tacrolimus concentrations by 3 methods 
We routinely measured blood tacrolimus concentrations by the MEIA method and compared these 
measurements and those obtained using the EMIT assay with LC/MS/MS data.  Although the MEIA or 
EMIT measurements were correlated with those obtained with the LC/MS/MS method, r2 values were 
relatively poor in EMIT measurements (Fig. 1).  We used LC/MS/MS data in the following analyses, 
because it is the most reliable method and because the MEIA method using an IMx analyzer will not be 
commercially available after 2010.   
 
Pharmacokinetic and pharmacodynamic profiles of tacrolimus 
We included 14 primary LDLT patients in this study.  The patients’ demographic characteristics 
are summarized in Table 1.  Figure 2 shows the time-course profiles of the blood tacrolimus concentration 
and CN activity at 1 and 3 weeks after LDLT.  Table 2 shows the corresponding pharmacokinetic and 
pharmacodynamic parameters for tacrolimus.  We could not obtain time-course data for 1 patient at 3 
weeks after LDLT because of the decease from infection.  The blood concentration profile at 3 weeks 
after LDLT changed gradually compared with that at 1 week, and the blood concentration at 1 h post-dose 
at 3 weeks was significantly lower than at 1 week (Fig. 2a).  The AUC0–12 was significantly smaller at 3 
weeks than at 1 week after LDLT (P < 0.05), although the morning dose tended to increase from 0.020 
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mg/kg at 1 week to 0.026 mg/kg at 3 weeks (Table 2).  Eleven of 13 patients showed an increase of CL/F 
at 3 weeks compared with that at 1 week, and this difference was statistically significant (Table 2, P<0.05).  
Thirteen patients would yield an 82% power to detect a 0.121 l/h/kg difference in CL/F (0.147 versus 
0.268 l/h/kg at 1 and 3 weeks, respectively) with a significant level of 0.05 (one-tailed test). 
The CN activity changed slightly and in parallel with the blood concentration, and returned to the 
pre-dose levels by 12 h post-dose at both 1 and 3 weeks after LDLT (Fig. 2b).  The CN activity at the 
trough time point (CN0) was suppressed to approximately 65% of the baseline value at 1 week, and CN0 at 
1 and 3 weeks after LDLT were not statistically significant (Table 2; Fig. 2).  
 
Correlation between blood concentration and AUC of tacrolimus 
The trough blood concentration before the morning dose (C0) and before the evening dose (C12) 
showed a high correlation with the AUC0–12 (Fig. 3; r2 = 0.767 to 0.888), although the correlation of C0 at 1 
week after LDLT was not so high (r2 = 0.530).  The blood concentrations at 2, 4, and 8 h post-dose also 
showed strong correlations with the AUC0–12, and the correlation with the blood concentration at 1 h 
post-dose was weak (r2 = 0.411 or 0.498).   
 
Relationship between blood concentration and CN activity  
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The CN activity in PBMCs was inhibited in a concentration-dependent manner by tacrolimus, but 
the inhibition was not complete even at blood tacrolimus concentrations more than 20 ng/ml (Fig. 4).  
Through the application of the Emax model to data from the 14 patients, we calculated the EC50 as 20.9 
ng/ml (95% confident interval: 11.6–30.2) and the Emax as 64.6 pmol/min/mg protein (95% confident 
interval: 56.3–72.9) by using the nonlinear mixed effects model. 
 
Correlation between tacrolimus exposure and pharmacodynamic response 
Both pharmacodynamic parameters CN0 and AUA0–12 did not correlate with C0 (Figs. 5a and b).  
The correlation between the AUA0–12 and the AUC0–12 was also weak (Fig. 5c).  However, the AUA0–12 
showed a strong correlation with CN0 activity (r2 = 0.919 or 0.931, Fig. 5d), as did CN activity at other 




LDLT and subsequent immunosuppressive therapy provide excellent results and are usually used in 
combination with a deceased donor organ-transplant program [14, 15].  Although the prevention of 
immunological reactions with sufficient immunosuppression prolongs graft and patient survival rates, the 
large inter-individual variation in tacrolimus pharmacokinetics interferes with treatment [16].  We 
previously reported that the probability of acute cellular rejection during the first 10 days after surgery was 
significantly associated with the average trough concentration of tacrolimus between PODs 2 and 4 [17].  
However, we had no clear evidence of the trough monitoring or AUC-based monitoring of tacrolimus 
blood concentration.  In this study, we confirmed that the trough blood concentration was a good 
surrogate marker for tacrolimus exposure during the dosing interval in LDLT patients. 
In the time-course study at 3 weeks after LDLT, tmax was prolonged and the difference between peak 
and trough concentrations was smaller compared with that at 1 week, indicating the delayed and poor 
absorption of tacrolimus at 3 weeks after LDLT (Fig. 2).  Although we cannot completely explain this 
phenomenon, the first-pass effects in the intestine and/or liver by cytochrome 3A and P-glycoprotein may 
be increased at 3 weeks after LDLT compared with at 1 week.  In addition, the apparent clearance of 
tacrolimus at 3 weeks after LDLT was approximately twice that at 1 week (Table 2).  We previously 
reported that the total-body clearance of tacrolimus in LDLT patients was increased according to the POD 
because of the regeneration of grafted liver [8, 9].  According to the previously estimated population 
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pharmacokinetic parameters [8], a typical adult LDLT recipient in this study (grafted liver weight of 611 g, 
normal hepatic and renal function, and body weight of 67.1 kg during week 1 and 63.5 kg during week 3) 
would have a CL/F of 0.186 L/h/kg on POD 7 and 0.241 L/h/kg on POD 21; these values are comparable 
to the mean CL/F in this study. 
We examined the correlation between AUC0–12 and blood concentration at each sampling point (Fig. 
3).  Although the correlation between the blood concentration at 1 h post-dose and the AUC0–12 was weak, 
other blood concentrations showed reasonable or strong correlations with the AUC0–12.  Since the blood 
concentration at 12 h post-dose (C12) will correlate with AUC0-12 for this dose and that C0 should correlate 
with AUC0-12 for the previous dose, C12 showed higher correlation than C0.  The relatively weak 
correlation found in C0 at 1 week after LDLT was considered due to a large variability in the 
pharmacokinetics of tacrolimus immediately after LDLT, similar to the findings in renal transplant 
recipients [5].  A good correlation between AUC from 0 to 24 h and trough concentrations for both 
twice-daily and once-daily prolonged tacrolimus formulations were reported in de novo kidney 
transplantation [18].  According to the previous report by Scholten et al. [5], Bayesian forecasting with a 
2-point sampling strategy, a trough level and a second sample obtained between 2 and 4 h post-dose, might 
improve the correlation with AUC0–12.  Taking these finding into consideration, we concluded that a 
single-trough concentration before the morning dose is sufficient to provide an index of blood tacrolimus 
exposure during the dosing interval in LDLT patients, even during the early post-transplantation period. 
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The CN activity changed in parallel with the blood tacrolimus concentration, and showed a similar 
flat time profile at 1 and 3 weeks after LDLT (Fig. 2).  These results indicated that unlike cyclosporine 
[12], tacrolimus partially suppressed CN activity throughout the dosing interval, probably because of the 
limited amount of active FK506-binding protein 12 in PBMCs [19].  The relationship between CN 
activity and blood tacrolimus concentration was analyzed using an Emax model with an EC50 of 20.9 ng/mL 
(Fig. 4), which is higher than the upper limit of the therapeutic range of tacrolimus, as discussed in our 
previous report [11].  Additionally, Fig. 4 showed a large inter-individual variability in the relation 
between tacrolimus exposure and CN activity.  This phenomenon may be explained by the 
inter-individual variability of expression level of P-glycoprotein in PBMCs [20] or variation in PBMC 
subset concentrations [21].   
We next examined the correlation between pharmacokinetic and pharmacodynamic parameters.  A 
single C0 did not correlate with CN0 or AUA0–12 (Figs. 5a, b).  In addition, as in our previous study of 
cyclosporine [12], the AUC0–12 of tacrolimus showed no relationship with AUA0–12 (Fig. 5c).  These 
results indicate a large inter-individual variability in the relationship between tacrolimus blood exposure 
and CN activity; monitoring of only tacrolimus blood concentrations does not adequately maintain CN 
activity at a targeted level, as reported by Blanchet et al. [22].  However, CN0 activity was strongly 
correlated with the AUA0–12 (Fig. 5d, r2 > 0.92).  We recently reported that CN activity rapidly increased 
a few days before the onset of acute rejection in 2 patients after living-donor kidney transplantation [23].  
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Therefore, monitoring CN activity at the trough time point would be useful for predicting the overall CN 
activity in LDLT patients administered tacrolimus.  In this study, we could not clarify the relationship 
between calcineurin activity and clinical outcomes, nor therapeutic range of calcineurin activity.  
Significance of measurements of calcineurin activity remains to be clarified in a large cohort of liver 
transplant recipients.  
In conclusion, we have shown that C0 monitoring of tacrolimus can be used to evaluate drug 
exposure in LDLT patients during the early post-transplantatation period, and that monitoring of CN 
activity at the trough time point could be useful to predict the immunological status during the dosing 
interval of tacrolimus. 
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Fig. 1  Correlation between the blood tacrolimus concentration by high-performance liquid 
chromatography with tandem mass spectrometry (LC/MS/MS) and microparticle enzyme immunoassay 
(MEIA) (a) or enzyme-multiplied immunoassay instrument (EMIT) (b) methods.  Each point shows a 
time-course datum from 14 patients at 1 week and 13 patients at 3 weeks after living-donor liver 
transplantation.  Solid and dotted lines show the linear regression line and the line of identity, 
respectively 
 
Fig. 2  Time course of blood tacrolimus concentration and calcineurin (CN) phosphatase activity in 
peripheral blood mononuclear cells at 1 week (open circles) and 3 weeks (closed circles) after living-donor 
liver transplantation.  Each symbol represents the mean ± standard deviation (n = 14 and 13 for 1 and 3 
weeks after transplantation, respectively).  *P < 0.05, significantly different from 1 week after 
transplantation 
 
Fig. 3  Correlation between area under the concentration-time curve from 0 to 12 h (AUC0-12) and blood 
tacrolimus concentration at pre-dose and 1, 2, 4, 8, and 12 h after the morning administration (C0, C1, C2, 
C4, C8, and C12, respectively).  Each point shows a datum from 14 patients at 1 week (open circles) and 13 
patients at 3 weeks (closed circles) after living-donor liver transplantation.  Each solid and dashed line 
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represents the linear regression line at 1 and 3 weeks, respectively  
 
Fig. 4  Relationship between blood tacrolimus concentration and calcineurin (CN) activity in living-donor 
liver transplant patients.  Each point shows a time-course datum from 14 patients at 1 week (open circles) 
and 13 patients at 3 weeks (closed circles) after living-donor liver transplantation.  Solid line shows the 
predicted calcineurin phosphatase activity versus the blood tacrolimus concentration profile according to 
the maximum inhibitory effect model by use of the nonlinear mixed effects modeling program   
 
Fig. 5  Correlation between pharmacokinetic and pharmacodynamic parameters (a, b, and c) and between 
pharmacodynamic parameters (d) of tacrolimus in 14 patients at 1 week (open circles) and 13 patients at 3 
weeks (closed circles) after living-donor liver transplantation.  Calcineurin activity at the trough time 
point (CN0, panel a) or the area under the calcineurin activity-time curve from 0 to 12 h (AUA0–12, panel b) 
versus blood concentration pre-dose (C0).  Panel c: AUA0–12 versus area under the concentration-time 
curve from 0 to 12 h (AUC0–12).  Panel d: AUA0–12 versus CN0 activity.  Each solid and dashed line 
represents the linear regression line at 1 and 3 weeks, respectively
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Table 1  Demographic characteristics of the study population 
Characteristic Number or mean ± standard deviation 
Gender (male/female) 8/6 
Age (years) 58 ± 6 
Grafted liver weight (g) 611 ± 156 
GRWR (%) 0.955 ± 0.184 
ABO blood group match  
     identical 7 
     compatible 5 
     incompatible 2 
Primary disease  
    Hepatitis B virus infection 3 
    Hepatitis C virus infection 6 
    Primary biliary cirrhosis 3 
    Alcoholic liver cirrhosis 1 
    Autoimmune hepatitis 1 
GRWR, graft-to-recipient weight ratio. 
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Table 2  Pharmacokinetic and pharmacodynamic parameters of tacrolimus  
Parameters Week1 (n = 14) Week3 (n = 13) 
Body weight (kg)  67.1 ± 15.2 63.5 ± 10.1 
Morning dose (mg/kg) 0.020 ± 0.015 0.026 ± 0.017 
Pharmacokinetic parameters   
  C0 (ng/ml) 9.8 ± 2.6 7.7 ± 2.7 
  tmax (h) 2 (1-8) 2 (0-4) 
  Cmax (ng/ml) 16.0 ± 5.4 12.5 ± 4.9 
  AUC0–12 (ng h/ml) 140 ± 38 110 ± 40* 
  CL/F (l/h/kg) 0.147 ± 0.110 0.268 ± 0.220* 
Pharmacodynamic parameters   
  CNbase (pmol/min/mg protein) 73.8 ± 16.2a -b 
  CN0 (pmol/min/mg protein) 47.9 ± 14.5 47.0 ± 11.2 
  tnadir (h) 2 4 
CNnadir (mg/min/mg protein)  40.6 ± 15.4 39.2 ± 9.7 
  AUA0–12 (pmol h/min/mg protein) 537 ± 188 512 ± 114 
Data are given as the mean ± SD or median (minimum-maximum).  an = 10.  bOnly measured on the day 
of transplantation.  *Significantly different from the mean value at week 1 (P < 0.05). 
C0, blood concentration pre-dose; Cmax, maximum blood concentration; tmax, time corresponding to Cmax; 
AUC0–12, area under the concentration-time curve from 0 to 12 h; CL/F, apparent clearance; CNbase, 
calcineurin activity at baseline measured before tacrolimus administration on the day of transplantation; 
CN0, calcineurin activity pre-dose; CNnadir, calcineurin activity at maximum inhibition; tnadir, time 
corresponding to CNnadir; AUA0–12, area under the calcineurin activity-time curve from 0 to 12 h. 
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